Visionary Pharmaceuticals, Inc., a San Diego, CA-based drug discovery company focused on new small molecule therapies in inflammation and cancer, has raised seed funding from a consortium of angel investors.
The company intends to use the capital, whose amount remained undisclosed, to develop novel small molecule retinoic acid related orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for the treatment of various autoimmune disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and COPD.
Led by President and CEO Gordon Alton, Ph.D., Visionary Pharmaceuticals has created an innovative drug discovery engine utilizing novel proprietary technology (BindingSIGHTs) to focus on nuclear hormone receptors, which represent 15% of all drugs approved in the US.
Along with the MANIFOLD virtual compound library, this technology provides advanced structural biology capabilities to optimize the development of drug candidates.
FinSMEs
27/07/2011